Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells

Yu Wei Chou, Nagendra K. Chaturvedi, Shougiang Ouyang, Fen Fen Lin, Dharam Kaushik, Jue Wang, Isaac Kim, Ming-Fong Lin

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression, an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished. Further, VPA pre-treatment enhanced androgen responsiveness of C-81, C4-2 and MDA PCa2b-AI cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells, and VPA pre-treatments increase androgen responsiveness.

Original languageEnglish (US)
Pages (from-to)177-186
Number of pages10
JournalCancer Letters
Volume311
Issue number2
DOIs
StatePublished - Dec 8 2011

Fingerprint

Histone Deacetylase Inhibitors
Valproic Acid
Androgens
Prostatic Neoplasms
Growth
Histones
Protein Tyrosine Phosphatases
Cyclins
Acetylation
Methylation
Small Interfering RNA
Proteins

Keywords

  • Androgen responsiveness
  • CPAcP
  • ErbB-2
  • HDAC inhibitors
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. / Chou, Yu Wei; Chaturvedi, Nagendra K.; Ouyang, Shougiang; Lin, Fen Fen; Kaushik, Dharam; Wang, Jue; Kim, Isaac; Lin, Ming-Fong.

In: Cancer Letters, Vol. 311, No. 2, 08.12.2011, p. 177-186.

Research output: Contribution to journalArticle

Chou, Yu Wei ; Chaturvedi, Nagendra K. ; Ouyang, Shougiang ; Lin, Fen Fen ; Kaushik, Dharam ; Wang, Jue ; Kim, Isaac ; Lin, Ming-Fong. / Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. In: Cancer Letters. 2011 ; Vol. 311, No. 2. pp. 177-186.
@article{210a83342587429eac2afab3360e6005,
title = "Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells",
abstract = "We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression, an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished. Further, VPA pre-treatment enhanced androgen responsiveness of C-81, C4-2 and MDA PCa2b-AI cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells, and VPA pre-treatments increase androgen responsiveness.",
keywords = "Androgen responsiveness, CPAcP, ErbB-2, HDAC inhibitors, Prostate cancer",
author = "Chou, {Yu Wei} and Chaturvedi, {Nagendra K.} and Shougiang Ouyang and Lin, {Fen Fen} and Dharam Kaushik and Jue Wang and Isaac Kim and Ming-Fong Lin",
year = "2011",
month = "12",
day = "8",
doi = "10.1016/j.canlet.2011.07.015",
language = "English (US)",
volume = "311",
pages = "177--186",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells

AU - Chou, Yu Wei

AU - Chaturvedi, Nagendra K.

AU - Ouyang, Shougiang

AU - Lin, Fen Fen

AU - Kaushik, Dharam

AU - Wang, Jue

AU - Kim, Isaac

AU - Lin, Ming-Fong

PY - 2011/12/8

Y1 - 2011/12/8

N2 - We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression, an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished. Further, VPA pre-treatment enhanced androgen responsiveness of C-81, C4-2 and MDA PCa2b-AI cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells, and VPA pre-treatments increase androgen responsiveness.

AB - We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression, an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished. Further, VPA pre-treatment enhanced androgen responsiveness of C-81, C4-2 and MDA PCa2b-AI cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells, and VPA pre-treatments increase androgen responsiveness.

KW - Androgen responsiveness

KW - CPAcP

KW - ErbB-2

KW - HDAC inhibitors

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=80053130009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053130009&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2011.07.015

DO - 10.1016/j.canlet.2011.07.015

M3 - Article

C2 - 21862211

AN - SCOPUS:80053130009

VL - 311

SP - 177

EP - 186

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -